Anti-tumor necrosis factor (anti-TNF) therapy has been successfully used as first-line
biologic treatment for moderate-to-severe inflammatory bowel disease (IBD), in both “step …

Psoriasis is a chronic, immune-mediated inflammatory disease with a worldwide prevalence
ranging between 0.51 and 11.43%. It results in a large clinical and social burden, with …

Background and Aims: Improving global health requires making current and future drugs
more effective and affordable. While healthcare systems around the world are faced with …

Chronic inflammation is closely related to chronic inflammatory diseases, autoimmune
diseases and cancer. Few studies have evaluated the effects of exposure to multiple …

Introduction This review provides an overview of data from trials and real-world studies
available for SB5 (ImraldiTM) across three main therapeutic areas: rheumatology …

Current biomarkers to assess the risk of complications of both acute and chronic viral
infection are suboptimal. Prevalent viral infections like human immunodeficiency virus (HIV) …

Background The non-interventional PROPER study generated real-world evidence on
clinical outcomes following transition in routine practice from reference adalimumab to the …

Summary Background and Aims Data on the outcomes after switching from adalimumab
(ADA) originator to ADA biosimilar are limited. The aim was to compare the treatment …

Purpose This review aims to provide an overview of the impact of TNFis biosimilars, with
marketing authorization, in patient-reported outcome measures (PROMs) scores and …

Objective: We aimed to assess the relative efficacy and safety of etanercept biosimilars and
etanercept originators in patients with active rheumatoid arthritis (RA) who showed an …